• PDF / 170,572 Bytes
• 1 Pages / 595.245 x 841.846 pts (A4) Page_size
• 71 Downloads / 191 Views

DOWNLOAD

REPORT

---

1 S

Various toxicities: 7 case reports A multi-centre prospective study [Study ID: NCT01072825] of 106 patients described two female to male transgender patients and five male to female transgender patients [ages not stated], who developed major depression, galactorrhoea, hypertension, skin irritation or muscle and joint aches during cross-sex hormone therapy (CHT) with cyproterone, estradiol, unspecified estrogen receptor agonists or testosterone-undecanoate [durations of treatments to reactions onsets not stated; not all routes, dosages and outcomes stated]. Seven patients had gender dysphoria. Therefore, they started receiving CHT. Two female to male transgender patients (transmen) received first IM testosterone-undecanoate 1000 mg injection [Nebido] at the start of the study, second injection at 6 weeks and thereafter every 12 weeks. Five male to female transgender patients received cyproterone [cyproterone acetate; Androcur] 50 mg/day plus transdermal estradiol [17-β-estradiol, Dermestril] 100 µg/24hours patch (2 patients) or cyproterone 50 mg/day plus unspecified estrogen receptor agonists (3 patients). Meanwhile, two transmen developed muscle and joint aches (n=2), which were attributed to testosterone-undecanoate, while the five transwomen developed major depression (n=1), galactorrhoea (n=1), hypertension (n=1) or skin irritation (n=2), which were attributed to cyproterone, estradiol patch or unspecified estrogen receptor agonists. The transmen were switched to short-acting IM testosterone esters after 9 months (1 patient) and 12 months (1 patient). The transwoman, who had developed major depression, discontinued the estrogen therapy. Galactorrhoea resolved spontaneously after several weeks. Two transwoman, who had developed skin irritation due to estradiol patches, were switched to other therapies after 3 months (1 patient) and 9 months (1 patient) of treatment. Wierckx K, et al. Cross-sex hormone therapy in trans persons is safe and effective at short-time follow-up: Results from the European network for the investigation of gender 803520127 incongruence. Journal of Sexual Medicine 11: 1999-2011, No. 8, Aug 2014. Available from: URL: http://doi.org/10.1111/jsm.12571

0114-9954/20/1834-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved

Reactions 12 Dec 2020 No. 1834